Skip to content

Author

Zexian Ding

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Jul 2026

RBCK1 promotes chemotherapy resistance in bladder carcinoma by targeting HLTF.

Integrated analysis of public transcriptomic datasets identify an RBCK1-HLTF-JAK2/STAT3 regulatory axis that promotes cisplatin resistance in bladder cancer cells, and xenograft validation further supports the role of RBCK1 depletion in enhancing cisplatin response in vivo.

Xin Yang, Ze-Xian Ding, Peng-Wang Ya et al. · 0 citations
Aug 2026

DHCR24+ tumor epithelial cells drive cisplatin resistance in bladder cancer by enhancing cholesterol metabolism to activate lipid raft-associated MAPK signaling.

This study characterizes a specific DHCR24+ tumor epithelial subpopulation that orchestrates cisplatin resistance via the "cholesterol-lipid raft-MAPK" axis and establishes a clear mechanistic link between cholesterol metabolism and cisplatin sensitivity.

Yuan-Qiao Zhao, Zhuo Xing, Mengmeng Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.